The Ante-Amyloid Treatment of Alzheimer's disease (A3) Trial and Alzheimer Plasma EXtension (APEX) Study
Funded Grant
Overview
Affiliation
View All
Overview
description
SUMMARY: This R01 application is to continue NIH funding for the Ante-Amyloid treatment of Alzheimer’s disease (A3) Trial and the Alzheimer Plasma Extension (APEX) Study. The A3 Trial is one of the sister trials of the AHEAD 3-45 Study testing lecanemab, a potent amyloid-removing monoclonal antibody, at the asymptomatic or “preclinical” stage of AD. The overall goal of these studies is to build a “bridging chain of evidence” that will link the removal of very early amyloid-beta (Aβ) to slowing the spread of early AD tauopathy and ultimately to the prevention of cognitive decline that occurs in the later stages of AD. The A3 Trial is testing low-dose lecanemab, prior (“ante”) to elevated brain amyloidosis, defined by intermediate levels (20-40 Centiloids) on screening Aβ PET. A3 runs in parallel with “A45” Trial, testing higher dose lecanemab in participants at later stages of preclinical AD (>40CL). The A3 Trial is the first prevention trial to test an amyloid-lowering therapeutic at the intermediate amyloid stage of sporadic AD and will contribute essential knowledge about the optimal window for efficacy and safety of anti-amyloid monotherapy. A3 is primarily an imaging and biofluid Phase IIb Study at a very early stage of AD pathophysiology, and will require longer term cognitive and functional assessments, paired with biofluid and imaging outcomes, through the Open-Label Extension to elucidate the links between Aβ, tau, and cognitive decline expected at the later preclinical stages studied in the A45 trial. AHEAD 3-45 Trials screened over 20,000 individuals ages 55-80 and recently completed randomization of both A3 (N=441) and A45 (N=1146), utilizing a novel plasma screening algorithm. The APEX Study, funded as a supplement to the A3 R01, will follow 1000 participants with subtle plasma abnormalities, but were not eligible due to amyloid PET below the A3 threshold (<20CL), oversampling from individuals from groups who showed disproportionate rates of ineligibility on screening Aβ and tau markers. APEX provides an unparalleled opportunity to evaluate longitudinal trajectories of AD biomarkers across all groups to inform future primary AD prevention trials. Furthermore, across APEX and A3-45, we will evaluate health factors, and novel markers of vascular and inflammatory processes to evaluate independent (and Aβ interactive) contributions to cognitive decline. This will lay the foundation for future prevention trials in populations in whom Aβ may not be the primary driver of dementia. Completing these public-private-philanthropic ACTC partnership projects will provide critical information to the field, in particular, whether lowering Aβ at this much earlier stage can halt the spread of tauopathy and have a greater impact on cognitive decline. These studies will serve to chart the path forward towards primary prevention of AD, as well as combination prevention trials to address the multiple contributors to cognitive decline in older individuals.
